Cargando…

Favipiravir and hyperuricemia in patients with COVID-19—suggestions for future studies

Detalles Bibliográficos
Autores principales:	Kow, Chia Siang, Ramachandram, Dinesh Sangarran, Hasan, Syed Shahzad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469911/ https://www.ncbi.nlm.nih.gov/pubmed/37662055 http://dx.doi.org/10.1016/j.lansea.2023.100267

Ejemplares similares

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Coenzyme Q10 therapy in patients with post COVID-19 condition
por: Kow, Chia Siang, et al.
Publicado: (2023)

How to make the best of NLRP3 inhibitors in patients with COVID-19?
por: Kow, Chia Siang, et al.
Publicado: (2023)

Hypertension and severe COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Insulin therapy in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)

Anakinra for the prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Statin use in patients with diabetes amid COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2021)

The use of corticosteroids in patients with COVID-19 vaccine–related cerebral venous thrombosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Probiotics for the Prevention of COVID-19 Sequelae
por: KOW, CHIA SIANG, et al.
Publicado: (2022)

Metformin therapy in COVID-19: inhibition of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

Aspirin Therapy in COVID-19: Prevention of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2023)

Statin Therapy in COVID-19: Inhibition of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

Use of sulforaphane in COVID-19: Clinical trials are needed
por: Kow, Chia Siang, et al.
Publicado: (2022)

Can COVID-19 vaccines improve cardiovascular outcomes?
por: Kow, Chia Siang, et al.
Publicado: (2022)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

Should COVID-19 be considered cardiovascular disease risk equivalent?
por: Kow, Chia Siang, et al.
Publicado: (2023)

The effect of vitamin C on the risk of mortality in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
por: Kow, Chia Siang, et al.
Publicado: (2023)

Metformin in COVID-19: clinical trials are needed to prove its benefits
por: Kow, Chia Siang, et al.
Publicado: (2022)

The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials
por: Kow, Chia Siang, et al.
Publicado: (2022)

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis
por: Kow, Chia Siang, et al.
Publicado: (2023)

Combination Therapy with CCBs and RAS Inhibitors to Counteract Endothelial Dysfunction in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2022)

Melatonin: Revisited Role as Vaccine Adjuvant During Outbreaks of COVID-19 Caused by the Delta Variant
por: Kow, Chia Siang, et al.
Publicado: (2021)

Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment
por: Kow, Chia Siang, et al.
Publicado: (2023)

Intermediate- to high-dose dexamethasone versus low-dose dexamethasone in patients with COVID-19 requiring respiratory support: a systematic review and meta-analysis of randomized trials
por: Kow, Chia Siang, et al.
Publicado: (2023)

Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
por: Kow, Chia Siang, et al.
Publicado: (2023)

Correction to: Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
por: Kow, Chia Siang, et al.
Publicado: (2023)

Hyperbaric oxygen therapy to reverse post-COVID cognitive impairment
por: Kow, Chia Siang, et al.
Publicado: (2022)

The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis
por: Kow, Chia Siang Chia, et al.
Publicado: (2022)

The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: a systematic review and meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2023)

IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Role of frailty in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials
por: Kow, Chia Siang, et al.
Publicado: (2021)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
por: Kow, Chia Siang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_786acusbi1vpn82j03vkdv6d1s